GlassScriptPhysician profile
Robert A Delapenha
NPI 1942351291
$4,485.34
in general payments reported to CMS, 2019-2025
11 companies · $791 in 2025
The $791 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $44.94 · 2020: $135 · 2021: $341 · 2022: $838 · 2023: $1,356 · 2024: $981 · 2025: $791.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,126.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $2,143.14 | 2019-2025 | Dovato, Cabenuva, Apretude |
| Gilead Sciences, INC. | $761.61 | 2020-2025 | Biktarvy, Sunlenca |
| Theratechnologies INC. | $589.38 | 2022-2025 | Egrifta, Trogarzo, Egrifta Sv |
| Janssen Biotech, INC. | $282.45 | 2019-2023 | Symtuza |
| Abbott Laboratories | $205.72 | 2023 | Id Now Instrument |
| Janssen Products, LP | $184.00 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $156.20 | 2022-2024 | Delstrigo, Pifeltro |
| Napo Pharmaceuticals INC | $87.43 | 2022-2023 | Mytesi |
| Janssen Pharmaceuticals, INC | $56.96 | 2021 | |
| Hologic Sales and Service, LLC | $18.45 | 2024 | Aptima |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Delapenha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.